Multiparametric MRI detects multi-organ impairment in patients with chronic myeloid neoplasms with normal serum biomarkers

medRxiv - Hematology Pub Date : 2023-11-23 DOI:10.1101/2023.11.23.23298558

Sophie Reed, Charlie Diamond, Samiya Mahmood, Soubera Rymell, Michael Smith, Michele Pansini, Bethan Psaila, Adam J. Mead, Helena Thomaides-Brears, Onima Chowdhury

{"title":"Multiparametric MRI detects multi-organ impairment in patients with chronic myeloid neoplasms with normal serum biomarkers","authors":"Sophie Reed, Charlie Diamond, Samiya Mahmood, Soubera Rymell, Michael Smith, Michele Pansini, Bethan Psaila, Adam J. Mead, Helena Thomaides-Brears, Onima Chowdhury","doi":"10.1101/2023.11.23.23298558","DOIUrl":null,"url":null,"abstract":"Assessment of organ impairment in patients with chronic myeloid neoplasms is pivotal in selecting treatments and for accurate prognostication of patient outcomes. In order to determine the multi-organ health of patients with chronic myeloid neoplasms, we conducted a prospective, observational study utilising a novel MRI technology which quantitatively assesses the health of multiple organs in one scan. Organ impairment was significantly higher in the patient cohort compared to healthy controls, most notably with increased rates of kidney fibroinflammation 28% vs 0% (p-value = 0.002). MRI-defined kidney impairment was prevalent in patients with normal serum biomarkers of kidney disease, demonstrating the added value of MRI as a tool to identify occult organ impairment. This has wider implications for enhancing the assessment of organ health in patients with a variety of blood cancers at diagnosis and throughout treatment, guiding more personalised strategies and improving patient outcomes.","PeriodicalId":501203,"journal":{"name":"medRxiv - Hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.11.23.23298558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Assessment of organ impairment in patients with chronic myeloid neoplasms is pivotal in selecting treatments and for accurate prognostication of patient outcomes. In order to determine the multi-organ health of patients with chronic myeloid neoplasms, we conducted a prospective, observational study utilising a novel MRI technology which quantitatively assesses the health of multiple organs in one scan. Organ impairment was significantly higher in the patient cohort compared to healthy controls, most notably with increased rates of kidney fibroinflammation 28% vs 0% (p-value = 0.002). MRI-defined kidney impairment was prevalent in patients with normal serum biomarkers of kidney disease, demonstrating the added value of MRI as a tool to identify occult organ impairment. This has wider implications for enhancing the assessment of organ health in patients with a variety of blood cancers at diagnosis and throughout treatment, guiding more personalised strategies and improving patient outcomes.

查看原文本刊更多论文

多参数MRI检测血清生物标志物正常的慢性髓系肿瘤患者的多器官损害

评估慢性髓系肿瘤患者的器官损害是选择治疗方法和准确预测患者预后的关键。为了确定慢性髓系肿瘤患者的多器官健康状况，我们进行了一项前瞻性观察性研究，利用一种新的MRI技术，在一次扫描中定量评估多个器官的健康状况。与健康对照组相比，患者队列中的器官损害明显更高，最明显的是肾纤维炎症发生率增加28%对0% (p值= 0.002)。MRI定义的肾脏损害在肾脏疾病血清生物标志物正常的患者中普遍存在，这证明了MRI作为识别隐匿性器官损害工具的附加价值。这对于加强各种血癌患者在诊断和整个治疗过程中的器官健康评估，指导更个性化的策略和改善患者预后具有更广泛的意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

medRxiv - Hematology

自引率

0.00%

发文量

文献相关原料

公司名称	产品信息	采购帮参考价格